Company news

Medicenna Therapeutics Corp. news in 2026

Medicenna Therapeutics Corp.'s news releases, calls and decks from 2026, newest first.

View company

Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders

November 4, 2026

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

October 26, 2026

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

October 22, 2026

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

October 5, 2026

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

October 1, 2026

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

September 24, 2026

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

August 14, 2026

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

June 26, 2026

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

June 11, 2026

Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

June 3, 2026

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

May 28, 2026

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

May 22, 2026

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

May 19, 2026

Medicenna Announces the Launch of a Marketed Public Offering of Securities

May 13, 2026

Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

May 12, 2026

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

April 30, 2026

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

April 21, 2026

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 14, 2026

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

April 9, 2026

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

March 18, 2026

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

February 13, 2026

Medicenna Announces Changes to Board Composition

February 13, 2026

Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

January 15, 2026

Decks in 2026